Therapeutic Options in Recurrent Soft Tissue Sarcoma

Therapeutic Options in Recurrent Soft Tissue Sarcoma

Episodes

Specialty:

All

Year:

All

EP. 1: When to Suspect Sarcoma

July 29th 2016

EP. 2: Soft Tissue Sarcoma: Factors Impacting Initial Approach

July 29th 2016

EP. 3: Challenges in Treating Soft Tissue Sarcomas in Younger Populations

July 29th 2016

EP. 4: Goals of Therapy in Sarcoma

July 29th 2016

EP. 5: Local Control in Metastatic Soft Tissue Sarcoma

July 29th 2016

EP. 6: Chemotherapy Sensitivity in Soft Tissue Sarcoma

July 29th 2016

EP. 7: Frontline Approach in Advanced Sarcomas

July 29th 2016

EP. 8: Sequencing Decisions in Soft Tissue Sarcoma

July 29th 2016

EP. 9: Recent Approvals in Soft Tissue Sarcoma

July 29th 2016

EP. 10: The Role of Trabectedin in Sarcoma Subtypes

July 29th 2016

EP. 11: Efficacy and Toxicities with Trabectedin in Sarcomas

July 29th 2016

EP. 12: Eribulin Mesylate in Soft Tissue Sarcoma

July 29th 2016

EP. 13: Olaratumab Efficacy in Soft-Tissue Sarcoma

July 29th 2016

EP. 14: Soft Tissue Sarcoma: Looking Ahead

July 29th 2016

Trending on OncLive

FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer

The OncFive: Top Oncology Articles for the Week of 9/14/2026

OncLive Weekly News Quiz (9/19/2026): Did You Catch the Latest NETs, Lung, Mastocytosis, and Pancreatic Cancer News?

Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma

Zipalertinib + Chemotherapy Extends PFS by 6 Months in Frontline EGFR Exon 20 Insertion–Positive NSCLC